Have You Tried Salonpas-HOT?

April 1, 2019

Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the marketers of the Salonpas® line of pain-relieving products, announce the availability of Salonpas®-HOT (SRP: $5.99), the top-selling product in the Topical Analgesic category*, in a new value pack that includes three folded patches in a pack.

“As our consumers typically purchase multiple Salonpas®-HOT patches at a time, we developed a 3-pack to provide better value and convenience for them,” said John Incledon, President & CEO, Hisamitsu America.  “The patches are the same size as the patch offered in the 1-count but are folded in half for packaging convenience and feature a resealable sachet to keep unused patches fresh.”

Salonpas® HOT releases capsaicin, a natural, odor free pain reliever, for long lasting pain relief up to eight hours. Capsaicin, the compound found in chili, cayenne, and jalapeno peppers, is used topically by many medical professionals to help relieve minor pain associated with arthritis or muscle sprains and strains.

“With all the opioid and Rx NSAID issues our country is facing, it is more important than ever to identify safer options to treat pain,” adds Incledon.  “the CDC has identified Topical Analgesics as a first line option in lieu of oral systemic analgesics and opioids, and specifically mention Capsaicin as one of the potential active ingredients.”

The new Salonpas®-HOT is available at retailers nationwide.

About Hisamitsu America:

Hisamitsu America is the US division of Hisamitsu Pharmaceutical Co., Inc., founded in 1847, which has specialized in transdermal drug delivery system technology since the introduction of its Salonpas line of patches in 1934. The Salonpas® product line, which gained early acceptance in Asia and now sells in over 30 countries, has pioneered the development of transdermal patches to relieve everyday aches and pains. Today, the Salonpas Pain Relief Patch LARGE is the first and only FDA-approved OTC pain reliever labeled to relieve mild to tougher, moderate pain. For more information, visit www.salonpas.us.

 

*Source: IRI Unit sales data for latest 52 weeks ending 2/24/19